var data={"title":"Everolimus: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Everolimus: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/243694?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">see &quot;Everolimus: Drug information&quot;</a> and <a href=\"topic.htm?path=everolimus-patient-drug-information\" class=\"drug drug_patient\">see &quot;Everolimus: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10223925\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Immunosuppression (Zortress):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Increased susceptibility to infection and the possible development of malignancies, such as lymphoma and skin cancer, may result from immunosuppression.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Only health care providers experienced in immunosuppressive therapy and management of transplant patients should use everolimus. Manage patients receiving the drug in facilities equipped and staffed with adequate laboratory and supportive medical resources. The health care provider responsible for maintenance therapy should have complete information requisite for the follow-up.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal graft thrombosis (Zortress):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">An increased risk of kidney arterial and venous thrombosis, resulting in graft loss, was reported, mostly within the first 30 days post-transplantation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrotoxicity (Zortress):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Increased nephrotoxicity can occur with use of standard doses of cyclosporine in combination with everolimus. Therefore, use reduced doses of cyclosporine in combination with everolimus in order to reduce renal dysfunction. It is important to monitor the cyclosporine and everolimus whole blood trough concentrations.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Mortality in heart transplant (Zortress):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Increased mortality, often associated with serious infection, within the first 3 months of post-transplantation was observed in a clinical trial of de novo heart transplant patients receiving immunosuppressive regimens with or without induction therapy. Use in heart transplantation is not recommended.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7418605\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Afinitor;</li>\n      <li>Afinitor Disperz;</li>\n      <li>Zortress</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13209898\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Afinitor;</li>\n      <li>Afinitor Disperz</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307736\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, mTOR Kinase Inhibitor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Immunosuppressant Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307778\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">see &quot;Everolimus: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Tablets (Afinitor, Zortress) and/or tablets for oral suspension (Afinitor Disperz) are not interchangeable. Afinitor Disperz is only indicated for the treatment of subependymal giant cell astrocytoma (SEGA), in conjunction with therapeutic monitoring. Do not combine formulations to achieve total desired dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Subependymal giant cell astrocytoma (SEGA):</b> Children &ge;1 year and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Afinitor; Afinitor Disperz: Oral: Initial: 4.5 mg/m<sup>2</sup> once daily; round to nearest tablet (tablet or tablet for oral suspension) size; continue until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Therapeutic drug monitoring: Assess trough concentration ~2 weeks after initiation or dosage modification, if dosage form switched (tablets or tablets for oral suspension), hepatic function changes, or concurrent therapy with a CYP3A4 or p-glycoprotein (P-gp) inducer or inhibitor is modified (initiated, dose change, or discontinued). Adjust maintenance dose if needed at 2-week intervals to achieve and maintain trough concentrations between 5 and 15 ng/mL; once stable dose is attained and BSA is stable throughout treatment, monitor trough concentrations every 6 to 12 months; monitor every 3-6 months if BSA is changing.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If trough &lt;5 ng/mL: Increase dose by 2.5 mg/day (tablets) or 2 mg/day (tablets for oral suspension).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If trough &gt;15 ng/mL: Reduce dose by 2.5 mg/day (tablets) or 2 mg/day (tablets for oral suspension). <b>Note:</b> If dose reduction necessary in patients receiving the lowest strength available, administer every other day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Transplantation; renal, rejection prophylaxis:</b> Zortress: Limited data available: Children &ge;1 year and Adolescents: Oral: Initial: 0.8 mg/m<sup>2</sup>/dose twice daily (maximum single dose: 1.5 mg) to maintain concentration: 3 to 6 ng/mL; reported start time of therapy variable: Within 48 hours post-transplantation was used in a multicenter, international trial of 19 pediatric patients; another trial began at 2 weeks after transplantation (single center, n=20 pediatric patients); a trial evaluating use for 3 years in pediatric patients (&lt;16 years), the mean reported dose was 1.53 mg/m<sup>2</sup>/day and no untoward adverse effects were noted (Ettenger, 2008; Hoyer, 2003; Pape, 2007; Pape, 2010; Pape, 2011; Van-Damme-Lombaerts, 2002; Vester, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast cancer, advanced, hormone receptor-positive, HER2-negative:</b> Afinitor: Oral: 10 mg once daily (in combination with exemestane); continue treatment until no longer clinically beneficial or until unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pancreatic neuroendocrine tumors, advanced (PNET):</b> Afinitor: Oral: 10 mg once daily; continue treatment until no longer clinically benefiting or until unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Renal cell cancer (RCC), advanced:</b> Afinitor: Oral: 10 mg once daily; continue treatment until no longer clinically benefiting or until unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Renal angiomyolipoma:</b> Afinitor: Oral: 10 mg once daily; continue treatment until no longer clinically beneficial or until unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Subependymal giant cell astrocytoma (SEGA):</b> Afinitor: Body surface area-based dosing: Oral: Initial dose: 4.5 mg/m<sup>2</sup> once daily; round to nearest tablet (tablet or tablet for oral suspension) size.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Therapeutic drug monitoring: Assess trough concentration ~2 weeks after initiation or dosage modification, if dosage form switched (tablets or tablets for oral suspension), hepatic function changes, or therapy with a CYP3A4 or p-glycoprotein (P-gp) inducer or inhibitor is modified (initiated, dose change, or discontinued). Adjust maintenance dose if needed at 2-week intervals to achieve and maintain trough concentrations between 5 and 15 ng/mL; once stable dose is attained and BSA is stable throughout treatment, monitor trough concentrations every 6 to 12 months; monitor every 3 to 6 months if BSA is changing.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If trough &lt;5 ng/mL: Increase dose by 2.5 mg/day (tablets) or 2 mg/day (tablets for oral suspension).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If trough &gt;15 ng/mL: Reduce dose by 2.5 mg/day (tablets) or 2 mg/day (tablets for oral suspension). <b>Note:</b> If dose reduction necessary in patients receiving the lowest strength available, administer every other day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Transplantation; liver, rejection prophylaxis (begin at least 30 days post-transplant):</b> Zortress: Oral: Initial: 1 mg twice daily; adjust maintenance dose if needed at a 4- to 5-day interval (from prior dose adjustment) based on concentrations, tolerability, and response; goal concentration is between 3 and 8 ng/mL (based on an LC/MS/MS assay method). If trough is &lt;3 ng/mL, double total daily dose (using available tablet strengths); if trough &gt;8 ng/mL on 2 consecutive measures, decrease dose by 0.25 mg twice daily. Administer in combination with tacrolimus (reduced dose required) and corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Transplantation; renal, rejection prophylaxis:</b> Zortress: Initial: 0.75 mg twice daily; adjust maintenance dose if needed at a 4- to 5-day interval (from prior dose adjustment) based on concentrations, tolerability, and response; goal concentration is between 3 and 8 ng/mL (based on an LCMSMS assay method). If trough is &lt;3 ng/mL, double total daily dose (using available tablet strengths); if trough &gt;8 ng/mL on 2 consecutive measures, decrease dose by 0.25 mg twice daily. <b>Note:</b> For use in renal transplantation, administer in combination with basiliximab induction and concurrently with cyclosporine (dose adjustment required) and corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for concomitant CYP3A4 inhibitors/inducers and/or P-glycoprotein (P-gp) inhibitors:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>SEGA:</b> Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CYP3A4/P-gp inducers: Strong inducers: Avoid concomitant administration with strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, St John's wort); if concomitant use cannot be avoided, an initial starting everolimus dose of 9 mg/m<sup>2</sup> once daily is recommended, or double the everolimus dose and assess tolerability; evaluate trough concentration after ~2 weeks; adjust dose as necessary based on therapeutic drug monitoring to maintain target trough concentrations of 5 to 15 ng/mL. If the strong CYP3A4/P-gp enzyme inducer is discontinued, reduce the everolimus by ~50% or to the dose used prior to initiation of the CYP3A4/P-gp inducer; reassess trough concentration after ~2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CYP3A4/P-gp inhibitors:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Strong inhibitors: Avoid concomitant administration with strong CYP3A4/P-gp inhibitors (eg, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate inhibitors (eg, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Initiating everolimus therapy with concurrent moderate CYP3A4/P-gp inhibitor:</i> Initial everolimus dose: 2.5 mg/m<sup>2</sup> once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Currently taking everolimus and starting a moderate CYP3A4/P-gp inhibitor:</i> Reduce everolimus dose by ~50%; if dose reduction is required for patients receiving the lowest strength available, consider alternate-day dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Discontinuing a moderate CYP3A4/P-gp inhibitor after concomitant use with everolimus:</i> Discontinue moderate inhibitor and allow 2 to 3 days to elapse prior to resuming the everolimus dose used prior to initiation of the moderate inhibitor.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Therapeutic drug monitoring:</i> Assess trough concentrations ~2 weeks after everolimus initiation or dosage modifications, or initiation or changes to concurrent CYP3A4/P-gp inhibitor therapy; adjust everolimus maintenance dose if needed at 2-week intervals to achieve and maintain trough concentrations between 5 and 15 ng/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Transplantation; renal:</b> Children and Adolescents: Dosage adjustments may be necessary based on everolimus whole blood trough concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> All patients: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mild hepatic impairment (Child-Pugh class A):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Breast cancer, PNET, RCC, renal angiomyolipoma:</b> Adults: Reduce dose to 7.5 mg once daily; if not tolerated, may further reduce to 5 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>SEGA:</b> Children, Adolescents, and Adults: Adjustment to initial dose may not be necessary; subsequent dosing is based on therapeutic drug monitoring (monitor 2 weeks after initiation, dosage modifications, or after any change in hepatic status; target trough concentration: 5-15 ng/mL).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Transplantation, liver or renal:</b> Adults: Reduce initial dose by ~33%; individualize subsequent dosing based on therapeutic drug monitoring (target trough concentration: 3 to 8 ng/mL).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate hepatic impairment (Child-Pugh class B):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Breast cancer, PNET, RCC, renal angiomyolipoma:</b> Adults: Reduce dose to 5 mg once daily if not tolerated, may further reduce to 2.5 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>SEGA:</b> Children, Adolescents, and Adults: Adjustment to initial dose may not be necessary; subsequent dosing is based on therapeutic drug monitoring (monitor 2 weeks after initiation, dosage modifications, or after any change in hepatic status; target trough concentration: 5 to 15 ng/mL).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Transplantation, liver or renal:</b> Adults: Reduce initial dose by ~50%; individualize subsequent dosing based on therapeutic drug monitoring (target trough concentration: 3 to 8 ng/mL).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe hepatic impairment (Child-Pugh class C):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Breast cancer, PNET, RCC, renal angiomyolipoma:</b> Adults: If potential benefit outweighs risks, a maximum dose of 2.5 mg once daily may be used.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>SEGA:</b> Children, Adolescents, and Adults: Reduce initial dose to 2.5 mg/m<sup>2</sup> once daily (or current dose by ~50%); subsequent dosing is based on therapeutic drug monitoring (monitor ~2 weeks after initiation, dosage modifications, or after any change in hepatic status; target trough concentration: 5 to 15 ng/mL).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Transplantation, liver or renal:</b> Adults: Reduce initial dose by ~50%; individualize subsequent dosing based on therapeutic drug monitoring (target trough concentration: 3 to 8 ng/mL).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>SEGA: </b>\n      <i>Severe/intolerable adverse reactions:</i> Temporarily interrupt or permanently discontinue treatment; if dose reduction is required upon reinitiation, reduce dose by ~50%; if dose reduction is required for patients receiving the lowest available strength, consider alternate day dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Transplantation, renal:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i> Evidence of polyoma virus infection or PML:</i> Consider reduced immunosuppression (taking into account the allograft risks associated with decreased immunosuppression).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Pneumonitis (grade 4 symptoms) or invasive systemic fungal infection:</i> Discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For other oncology uses, the following have been used in adult patients:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adult: <b>Breast cancer (adjustments apply to everolimus), PNET, RCC, renal angiomyolipoma:</b> Toxicities may require temporary dose interruption (with or without a subsequent dose reduction) or discontinuation: Reduce everolimus dose by ~50% if dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Noninfectious pneumonitis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 1 (asymptomatic radiological changes suggestive of pneumonitis): No dosage adjustment necessary; monitor appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 2 (symptomatic but not interfering with activities of daily living [ADL]): Consider interrupting treatment, rule out infection, and consider corticosteroids until symptoms improve to &le;grade 1; reinitiate at a lower dose. Discontinue if recovery does not occur within 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 3 (symptomatic, interferes with ADL; oxygen indicated): Interrupt treatment until symptoms improve to &le;grade 1; rule out infection and consider corticosteroid treatment; may reinitiate at a lower dose. If grade 3 toxicity recurs, consider discontinuing.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 4 (life-threatening; ventilatory support indicated): Discontinue treatment; rule out infection; consider corticosteroid treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Stomatitis (avoid the use of products containing alcohol, hydrogen peroxide, iodine, or thyme derivatives):</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 1 (minimal symptoms, normal diet): No dosage adjustment necessary; manage with mouth wash (nonalcoholic or salt water) several times a day.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 2 (symptomatic but can eat and swallow modified diet): Interrupt treatment until symptoms improve to &le;grade 1; reinitiate at same dose; if stomatitis recurs at grade 2, interrupt treatment until symptoms improve to &le;grade 1 and then reinitiate at a lower dose. Also manage with topical (oral) analgesics (eg, benzocaine, butyl aminobenzoate, tetracaine, menthol, or phenol) &plusmn; topical (oral) corticosteroids (eg, triamcinolone oral paste).</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 3 (symptomatic and unable to orally aliment or hydrate adequately): Interrupt treatment until symptoms improve to &le;grade 1; then reinitiate at a lower dose. Also manage with topical (oral) analgesics (eg, benzocaine, butyl aminobenzoate, tetracaine, menthol, or phenol) &plusmn; topical (oral) corticosteroids (eg, triamcinolone oral paste).</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 4 (life-threatening symptoms): Discontinue treatment; initiate appropriate medical intervention.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Metabolic toxicity (eg, hyperglycemia, dyslipidemia):</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 1: No dosage adjustment necessary; initiate appropriate medical intervention and monitor.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 2: No dosage adjustment necessary; manage with appropriate medical intervention and monitor.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 3: Temporarily interrupt treatment; reinitiate at a lower dose; manage with appropriate medical intervention and monitor.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 4: Discontinue treatment; manage with appropriate medical intervention.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Nonhematologic toxicities (excluding pneumonitis, stomatitis, and metabolic toxicity):</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 1: If toxicity is tolerable, no dosage adjustment necessary; initiate appropriate medical intervention and monitor.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 2: If toxicity is tolerable, no dosage adjustment necessary; initiate appropriate medical intervention and monitor. If toxicity becomes intolerable, temporarily interrupt treatment until improvement to &le;grade 1 and reinitiate at the same dose; if toxicity recurs at grade 2, temporarily interrupt treatment until improvement to &le;grade 1 and then reinitiate at a lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 3: Temporarily interrupt treatment until improvement to &le;grade 1; initiate appropriate medical intervention and monitor. May reinitiate at a lower dose; if toxicity recurs at grade 3, consider discontinuing.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Grade 4 (life-threatening symptoms): Discontinue treatment; initiate appropriate medical intervention.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7674251\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afinitor: 2.5 mg, 5 mg, 7.5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zortress: 0.25 mg, 0.5 mg, 0.75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Soluble, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afinitor Disperz: 2 mg, 3 mg, 5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7674088\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10223926\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication;</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zortress: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021560s020lbl.pdf#page=32&amp;token=D9IOjNQ6xnijnOYBx34L55yI6Km+YLYkP2oyjK8315kHb46eSqbOQdYEbTtyfjyC1KEikOM9d8eHoBTAUq0Hk9uD+oZ072tFvZc13pB0QawIYfv+fCuXRL4XWv8W/olb&amp;TOPIC_ID=17063\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021560s020lbl.pdf#page=32</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307877\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">To avoid potential contact with everolimus, caregivers should wear gloves when preparing suspension from tablets for oral suspension.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be taken with or without food; to reduce variability, take consistently with regard to food; if using for SEGA, breast cancer, PNET, renal angiolipoma, or RCC, administer at the same time each day; if using for liver or renal transplantation, administer consistently ~12 hours apart and at the same time as tacrolimus (liver transplant) or cyclosporine (renal transplant).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Swallow tablet whole with a glass of water; do not chew or crush; do not use tablets that are crushed or broken; avoid contact with or exposure to crushed or broken tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets for oral suspension: Administer as a suspension only. Administer immediately after preparation; discard if not administered within 60 minutes after preparation. Prepare suspension in water only. Do not break or crush tablets. May be prepared in an oral syringe or small glass.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132489\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7674865\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Tablets and tablets for suspension: Store at room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light; protect from moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307737\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Afinitor: Treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) which requires intervention, but cannot be curatively resected (FDA approved in ages &ge;1 year and adults); treatment of advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (in combination with exemestane and after letrozole or anastrozole failure (FDA approved in adults); treatment of advanced renal cell cancer (RCC), after sunitinib or sorafenib failure (FDA approved in adults); treatment of renal angiomyolipoma with TSC not requiring immediate surgery (FDA approved in adults); treatment of advanced, metastatic, or unresectable pancreatic neuroendocrine tumors (PNET) (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Afinitor Disperz: Treatment of SEGA associated with TSC which requires intervention, but cannot be curatively resected (FDA approved in ages &ge;1 year and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zortress: Prophylaxis of organ rejection in patients at low-moderate immunologic risk receiving renal or liver transplants (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7674085\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Everolimus may be confused with sirolimus, tacrolimus, temsirolimus</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Afinitor may be confused with afatinib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tablets (Afinitor, Zortress) and tablets for oral suspension (Afinitor Disperz) are not interchangeable; do not combine formulations to achieve total desired dose. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7674167\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Transplantation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reactions occur in kidney and liver transplantation unless otherwise specified.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, atrial fibrillation, cardiac failure, chest discomfort, chest pain, deep vein thrombosis, edema, hypertension (more common in kidney transplant), hypertensive crisis, hypotension, palpitations, peripheral edema (more common in kidney transplant), pulmonary embolism, renal artery thrombosis, syncope, tachycardia, venous thromboembolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, anxiety, chills, depression, dizziness, drowsiness, fatigue, hallucination, headache, hemiparesis, hypoesthesia, insomnia (kidney transplant), lethargy, malaise, migraine, myasthenia, neuralgia, pain, paresthesia, procedural pain (kidney transplant)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acneiform eruption, acne vulgaris, alopecia, cellulitis, diaphoresis, folliculitis, hypertrichosis, night sweats, onychomycosis, pruritus, skin rash, tinea pedis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acidosis, amenorrhea, cushingoid appearance, cyanocobalamin deficiency, dehydration, diabetes mellitus (new onset: more common in liver transplant), fluid retention, gout, hirsutism, hypercalcemia, hypercholesterolemia, hyperglycemia (kidney transplant), hyperkalemia (renal transplant), hyperparathyroidism, hypertriglyceridemia, hyperuricemia, hypocalcemia, hypoglycemia, hypokalemia (kidney transplant), hypomagnesemia (kidney transplant), hyponatremia, hypophosphatemia (kidney transplant), iron deficiency, ovarian cyst</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, abdominal pain (less common in upper abdominal pain, kidney transplant), anorexia, constipation (kidney transplant), decreased appetite, diarrhea, dyspepsia (kidney transplant), dysphagia, epigastric distress, flatulence, gastroenteritis, gastroesophageal reflux disease, gingival hyperplasia, hematemesis, hemorrhoids, intestinal obstruction, nausea (more common in kidney transplant), oral candidiasis, oral herpes, oral mucosa ulcer, peritoneal effusion, peritonitis, stomatitis (kidney transplant), vomiting (kidney transplant)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Bladder spasm, dysuria (kidney transplant), erectile dysfunction (kidney transplant), hematuria (kidney transplant), perinephric abscess, perinephric hematoma, pollakiuria, proteinuria, pyuria, scrotal edema, urethritis, urinary retention, urinary tract infection (kidney transplant), urinary urgency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (kidney transplant), leukocytosis, leukopenia, lymphadenopathy, lymphorrhea, neoplasm, neutropenia, pancytopenia, thrombocythemia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests (liver transplant), ascites (liver transplant), hepatitis (noninfections), increased liver enzymes, increased serum alkaline phosphatase, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Bacteremia, bacterial infection (liver transplant), BK virus (kidney transplant), candidiasis, hepatitis C (liver transplant), herpes virus infection, infection (more common in kidney transplant), influenza, sepsis, viral infection (more common in liver transplant), wound infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Incisional pain (kidney transplant)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain (kidney transplant), joint swelling, limb pain (kidney transplant), muscle spasm, musculoskeletal pain, myalgia, osteomyelitis, osteonecrosis, osteoporosis, spondylitis, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, cataract, conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Hydronephrosis, increased blood urea nitrogen, increased serum creatinine (kidney transplant), interstitial nephritis, polyuria, pyelonephritis, renal failure (acute), renal insufficiency, renal tubular necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Atelectasis, bronchitis, cough (kidney transplant), dyspnea, epistaxis, lower respiratory tract infection, nasal congestion, nasopharyngitis, oropharyngeal pain, pleural effusion, pneumonia, pulmonary edema, rhinorrhea, sinus congestion, sinusitis, upper respiratory tract infection (kidney transplant), wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, postoperative wound complication (more common in kidney transplant; includes incisional hernia, lymphocele, seroma, wound dehiscence)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Antineoplastic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antineoplastic indications include advanced hormone receptor-positive, advanced nonfunctional NET of gastrointestinal or lung origin, HER2-negative breast cancer (advanced HR + BC), pancreatic neuroendocrine tumors (PNET), renal cell carcinoma (RCC), renal angiomyolipoma and tuberous sclerosis complex (TSC), and subependymal giant cell astrocytoma (SEGA)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain (RCC), cardiac failure (RCC), deep vein thrombosis (RCC), edema (PNET), hypertension (PNET, RCC, SEGA), peripheral edema (more common in advanced nonfunctional NET of gastrointestinal or lung origin, PNET), tachycardia (RCC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Behavioral problems (SEGA; includes abnormal behavior, aggressive behavior, agitation, anxiety, obsessive compulsive symptoms, panic attack), chills (RCC), depression (TSC), dizziness (PNET, RCC), fatigue (more common in advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin, PNET, RCC), headache (more common in PNET), insomnia (advanced HR + BC, PNET, RCC, SEGA), malaise (PNET), migraine (PNET), paresthesia (RCC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acneiform eruption (RCC), acne vulgaris (more common in TSC), alopecia (advanced HR + BC), cellulitis (SEGA), erythema (RCC), nail disease (more common in PNET), onychoclasis (RCC), palmar-plantar erythrodysesthesia (RCC), pruritus (advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin, PNET, RCC), skin lesion (RCC), skin rash (more common in PNET; may include allergic dermatitis, macular eruption, maculopapular rash, papular rash, urticaria), xeroderma (PNET, RCC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Amenorrhea (TSC, SEGA), decreased serum bicarbonate (PNET), decreased serum calcium (PNET), decreased serum fibrinogen (SEGA), diabetes mellitus (more common in PNET), hypercholesterolemia (more common in TSC, SEGA), hyperglycemia (more common in advanced nonfunctional NET of gastrointestinal or lung origin), hypermenorrhea (TSC, SEGA), hypertriglyceridemia (more common in TSC), hypoalbuminemia (advanced nonfunctional NET of gastrointestinal or lung origin), hypokalemia (advanced nonfunctional NET of gastrointestinal or lung origin), hypophosphatemia (more common in advanced nonfunctional NET of gastrointestinal or lung origin, TSC), increased follicle-stimulating hormone (TSC), increased luteinizing hormone (TSC, SEGA), menstrual disease (TSC, SEGA), ovarian cyst (TSC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (more common in PNET), anorexia (RCC), constipation (advanced HR + BC, PNET, SEGA), decreased appetite (more common in advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin, PNET), diarrhea (more common in advanced nonfunctional NET of gastrointestinal or lung origin, PNET; may include bowel urgency, colitis, enteritis, enterocolitis, steatorrhea), dysgeusia (more common in advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin, PNET), dysphagia (RCC), gastroenteritis (SEGA; includes viral gastroenteritis, gastrointestinal infection), hemorrhoids (RCC), mucositis (RCC), nausea (more common in advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin, RCC), stomatitis (more common in advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin, PNET, SEGA, TSC), vomiting, weight loss (more common in advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin, PNET), xerostomia (advanced HR + BC, PNET, RCC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Cystitis (advanced HR + BC), dysmenorrhea (SEGA), irregular menses (TSC, PNET), urinary tract infection (more common in PNET), uterine hemorrhage (SEGA), vaginal hemorrhage (TSC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (more common in advanced nonfunctional NET of gastrointestinal or lung origin), hemorrhage (RCC), increase in fasting plasma glucose (more common in PNET), leukopenia (more common in advanced nonfunctional NET of gastrointestinal or lung origin), lymphocytopenia (more common in advanced nonfunctional NET of gastrointestinal or lung origin), neutropenia (more common in SEGA), prolonged partial thromboplastin time (SEGA), thrombocytopenia (more common in advanced nonfunctional NET of gastrointestinal or lung origin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase (more common in PNET), increased serum ALT (more common in advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin, PNET), increased serum AST (more common in advanced HR + BC), increased serum bilirubin (RCC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema (RCC, TSC), hypersensitivity reaction (TSC, SEGA; includes anaphylaxis, chest pain, dyspnea, flushing)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Candidiasis (advanced HR + BC, RCC), hepatitis C (advanced HR + BC), infection (more common in advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin), sepsis (advanced HR + BC, RCC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (advanced HR + BC, PNET, TSC), back pain (advanced HR + BC, PNET), jaw pain (RCC), limb pain (PNET, RCC, SEGA), muscle spasm (PNET), weakness (more common in RCC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Eyelid edema (RCC), conjunctivitis (RCC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otitis media (TSC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine (more common in RCC), renal failure (RCC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis (advanced HR + BC, RCC), cough (advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin, PNET, RCC, TSC; includes productive cough), dyspnea (more common in advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin, PNET, RCC; includes dyspnea on exertion), epistaxis (advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin, PNET, RCC, TSC, SEGA), nasopharyngitis (more common in PNET), oropharyngeal pain (PNET), pharyngolaryngeal pain (RCC), pleural effusion (RCC), pneumonia (advanced HR + BC, RCC, SEGA), pneumonitis (more common in advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin, PNET, RCC; may include interstitial pulmonary disease, pulmonary alveolar hemorrhage, pulmonary alveolitis, pulmonary fibrosis, pulmonary infiltrates, pulmonary toxicity, restrictive pulmonary disease), respiratory tract infection (SEGA; includes viral respiratory tract infection), rhinitis (PNET), rhinorrhea (RCC), sinusitis (advanced HR + BC, RCC), streptococcal pharyngitis (SEGA), upper respiratory tract infection (more common in PNET)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (advanced HR + BC, advanced nonfunctional NET of gastrointestinal or lung origin, PNET, RCC, SEGA), postoperative wound complication (RC; wound healing impairment),</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Arterial thrombosis, aspergillosis, azoospermia, cholecystitis, cholelithiasis, complex regional pain syndrome, decreased plasma testosterone, hemolytic uremic syndrome, hypersensitivity angiitis, male infertility, nephrotoxicity, oligospermia, pancreatitis (including acute pancreatitis), pericardial effusion, pneumonia (<i>Pneumocystis jirovecii)</i>, polyoma virus infection, progressive multifocal leukoencephalopathy, reactivation of HBV, respiratory distress, thrombosis of vascular graft (kidney), thrombotic thrombocytopenic purpura</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7674098\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to everolimus, sirolimus, other rapamycin derivatives, or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Treatment of seizures (any type) in populations other than those with a definite tuberous sclerosis complex (TSC) diagnosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7674099\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Angioedema: Everolimus is associated with the development of angioedema; concomitant use with other agents known to cause angioedema (eg, ACE inhibitors) may increase the risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Decreases in hemoglobin, neutrophils, platelets, and lymphocytes have been reported. Monitor blood counts at baseline and periodically.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Edema: Generalized edema (including peripheral edema and lymphedema) and local fluid accumulation (eg, pericardial effusion, pleural effusion, ascites) may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fertility effects: May cause infertility. In females, menstrual irregularities, secondary amenorrhea, and increases in luteinizing hormone and follicle-stimulating hormone have occurred. Azoospermia and oligospermia have been observed in males.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Graft thrombosis: <b>[US Boxed Warning]: An increased risk of renal arterial and venous thrombosis has been reported with use in renal transplantation, generally within the first 30 days after transplant; may result in graft loss.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic artery thrombosis: MTOR inhibitors are associated with an increase in hepatic artery thrombosis, most cases have been reported within 30 days after transplant and usually proceeded to graft loss or death. Do not use everolimus prior to 30 days post liver transplant.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Everolimus has immunosuppressant properties which may result in infection;</b> the risk of developing bacterial (including mycobacterial), viral, fungal, and protozoal infections and for local, opportunistic (including polyomavirus infection), and/or systemic infections is increased; may lead to sepsis, respiratory failure, hepatic failure, or fatality. Polyoma virus infection in transplant patients may be serious and/or fatal. Polyoma virus-associated nephropathy (due to BK virus), which may result in serious cases of deteriorating renal function and renal graft loss, has been observed with use in renal transplantation. JC virus-associated progressive multiple leukoencephalopathy (PML) may also be associated with everolimus use in transplantation. Reduced immunosuppression (taking into account the risks of rejection) should be considered with evidence of polyoma virus infection or PML. Reactivation of hepatitis B has been observed in patients receiving everolimus. Resolve preexisting invasive fungal infections prior to treatment initiation. Cases (some fatal) of <i>Pneumocystis jirovecii</i> pneumonia (PCP) have been reported with everolimus use. Consider PCP prophylaxis in patients receiving concomitant corticosteroid or other immunosuppressant therapy. In addition, transplant recipient patients should receive prophylactic therapy for PCP and for cytomegalovirus (CMV). Monitor for signs and symptoms of infection during treatment. Discontinue if invasive systemic fungal infection is diagnosed (and manage with appropriate antifungal therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Immunosuppressant use may result in the development of malignancy, including lymphoma and skin cancer.</b> The risk is associated with treatment intensity and the duration of therapy. To minimize the risk for skin cancer, limit exposure to sunlight and ultraviolet light; wear protective clothing, and use effective sunscreen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Metabolic effects: Hyperglycemia, hyperlipidemia, and hypertriglyceridemia have been reported. Higher serum everolimus concentrations are associated with an increased risk for hyperlipidemia. Use has not been studied in patients with baseline cholesterol &gt;350 mg/dL. Monitor fasting glucose and lipid profile prior to treatment initiation and periodically thereafter. Monitor more frequently in patients with concomitant medications affecting glucose. Increases in serum glucose are common; may alter insulin and/or oral hypoglycemic therapy requirements in patients with diabetes. The risk for new-onset diabetes is increased with everolimus use after transplantation. Manage with appropriate medical therapy (if possible, optimize glucose control and lipids prior to treatment initiation). Antihyperlipidemic therapy may not normalize levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mucositis/stomatitis: Everolimus is associated with mouth ulcers, mucositis, and stomatitis. Stomatitis typically occurs within the first 8 weeks of therapy. When used for oncology indications, dexamethasone 0.5 mg/5 mL alcohol-free oral solution mouthwash (10 mL swish and spit 4 times/day) may reduce the incidence and severity of stomatitis if initiated at the onset of everolimus treatment (avoid food or drink within 1 hour after dexamethasone). If stomatitis does occur, manage with topical therapy; avoid the use of alcohol-, hydrogen peroxide&ndash;, iodine-, or thyme-based mouthwashes. Due to the high potential for drug interactions, avoid the use of systemic antifungals unless fungal infection has been diagnosed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: Elevations in serum creatinine (generally mild), renal failure, and proteinuria have been observed with everolimus use; monitor renal function (BUN, creatinine, and/or urinary protein). Risk of nephrotoxicity may be increased when administered with calcineurin inhibitors (eg, cyclosporine, tacrolimus); dosage adjustment of calcineurin inhibitor is necessary. Monitor for proteinuria; the risk of proteinuria is increased when everolimus is used in combination with cyclosporine, and with higher serum everolimus concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Noninfectious pneumonitis, interstitial lung disease (ILD), and/or noninfectious fibrosis have been observed with mTOR inhibitors, including everolimus; some cases were fatal. Symptoms include dyspnea, cough, hypoxia and/or pleural effusion; promptly evaluate worsening respiratory symptoms. Cases of ILD have been reported with pulmonary hypertension (including pulmonary arterial hypertension) as a secondary event. Consider opportunistic infections such as <i>Pneumocystis jirovecii</i> pneumonia (PCP) when evaluating clinical symptoms. May require treatment interruption followed by dose reduction (pneumonitis has developed even with reduced doses) and/or corticosteroid therapy; discontinue for grade 4 pneumonitis. Consider discontinuation for recurrence of grade 3 toxicity after dosage reduction. In patients who require steroid therapy for symptom management, consider PCP prophylaxis. Imaging may overestimate the incidence of clinical pneumonitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wound healing complication: Everolimus use may delay wound healing and increase the occurrence of wound-related complications (eg, wound dehiscence, infection, incisional hernia, lymphocele, seroma); may require surgical intervention. Use everolimus with caution in the peri-surgical period.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart transplantation: <b>[US Boxed Warning]: Increased mortality (usually associated with infections) within the first 3 months after transplant was noted in a study of patients with <i>de novo</i> heart transplant receiving immunosuppressive regimens containing everolimus (with or without induction therapy). Use in heart transplantation is not recommended.</b> The boxed warning in the labeling (Zortress) is based on severe infectious complications, rather than efficacy (reduction in the incidence of cardiac allograft vasculopathy). Despite labeled warnings for this off-label indication, some centers continue to use everolimus (with reduced calcineurin inhibitor exposure). However, everolimus initiation in heart transplantation is delayed until 3 to 6 months post-transplantation due to impaired wound healing and pericardial effusions early on in the postoperative period (Andreassen 2014; Andreassen 2016; Costanza 2010; Hirt 2013; Hollis 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Everolimus exposure is increased in patients with hepatic impairment. For patients with breast cancer, neuroendocrine tumors, RCC, or renal angiomyolipoma with mild and moderate hepatic impairment, reduced doses are recommended; in patients with severe hepatic impairment, use is recommended (at reduced doses) if the potential benefit outweighs risks. Reduced doses are recommended in transplant patients with hepatic impairment (Child-Pugh class A, B, or C); monitor whole blood trough levels closely. For patients with SEGA, reduced doses may be needed (based on therapeutic drug monitoring) for mild and moderate hepatic impairment, and are recommended in severe hepatic impairment; monitor whole blood trough levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hereditary galactose intolerance: Avoid use in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption; may result in diarrhea and malabsorption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: An increased incidence of rash, infection and dose interruptions have been reported in patients with renal insufficiency (CrCl &le;60 mL/minute) who received mTOR inhibitors for the treatment of renal cell cancer (Gupta 2011). Serum creatinine elevations and proteinuria have been reported. Monitor renal function (BUN, serum creatinine, urinary protein) at baseline and periodically, especially if risk factors for further impairment exist. Pharmacokinetic studies have not been conducted; dosage adjustments are not required based on renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transplantation (solid organ): The safety and efficacy of everolimus in renal transplantation patients with high-immunologic risk or in solid organ transplant other than renal or liver have not been established. In liver transplant, tacrolimus has minimal or no pharmacokinetic impact on everolimus concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Calcineurin inhibitor combination therapy: <b>[US Boxed Warning]: Due to the increased risk for nephrotoxicity in renal transplantation, avoid standard doses of cyclosporine in combination with everolimus; reduced cyclosporine doses are recommended when everolimus is used in combination with cyclosporine. Therapeutic monitoring of cyclosporine and everolimus concentrations is recommended.</b> Everolimus and cyclosporine combination therapy may result in increased proteinuria and may increase the risk for thrombotic microangiopathy/thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TMA/TTP/HUS); monitor blood counts. In liver transplantation, the tacrolimus dose and target range should be reduced to minimize the risk of nephrotoxicity. Eliminating calcineurin inhibitors from the immunosuppressive regimen may result in acute rejection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HMG-CoA reductase inhibitors: In transplant patients, avoid the use of certain HMG-CoA reductase inhibitors (eg, simvastatin, lovastatin); may increase the risk for rhabdomyolysis due to the potential interaction with cyclosporine (which may be given in combination with everolimus for transplantation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tablet formulations: Tablets (Afinitor, Zortress) and tablets for oral suspension (Afinitor Disperz) are not interchangeable; Afinitor Disperz is only indicated in conjunction with therapeutic monitoring for the treatment of SEGA. Do not combine formulations to achieve total desired dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Continue treatment with everolimus for renal cell cancer as long as clinical benefit is demonstrated or until occurrence of unacceptable toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Assay method: For indications requiring whole blood trough concentrations to determine dosage adjustments, a consistent method should be used; concentration values from different assay methods may not be interchangeable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: In transplantation, everolimus should only be used by physicians experienced in immunosuppressive therapy and management of transplant patients. Adequate laboratory and supportive medical resources must be readily available.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should not be immunized with live viral vaccines during or shortly after treatment and should avoid close contact with recently vaccinated (live vaccine) individuals. In pediatric patients treated for SEGA, complete recommended series of live virus childhood vaccinations prior to treatment (if immediate everolimus treatment is not indicated); an accelerated vaccination schedule may be appropriate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9837969\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7710406\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=17063&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Everolimus may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Everolimus.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of Everolimus. Management: When using everolimus for renal cell carcinoma, avoid concurrent cyclosporine.  When using everolimus as post-transplant immunosuppression, concurrent cyclosporine should be used at lower doses and with lower target serum cyclosporine concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Everolimus. Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Everolimus. Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Everolimus.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Everolimus. Management: Closely monitor everolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of everolimus may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Everolimus.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Everolimus. Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of Everolimus.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Everolimus. Management: Concurrent use of Afinitor brand everolimus with St Johns wort (SJW) is not recommended. Zortress brand everolimus prescribing information cautions that SJW may decrease everolimus concentrations, though no specific dose adjustment is recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May increase the serum concentration of Everolimus. Management: Administer everolimus at least 6 hours before venetoclax when concomitant therapy is required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Everolimus.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7674191\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice may increase levels of everolimus. Absorption with food may be variable. Management: Avoid grapefruit juice. Take with or without food, but be consistent with regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7674094\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Based on the mechanism of action and data from animal reproduction studies, everolimus may cause fetal harm if administered during pregnancy. Information related to the use of everolimus in pregnancy is limited (Yamamura 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Females of reproductive potential should be advised to avoid pregnancy and use highly effective birth control during treatment and for 8 weeks after the last everolimus dose. Male patients with female partners of reproductive potential should use effective contraception during treatment and for 4 weeks after the last everolimus dose.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Everolimus may cause infertility. In females, menstrual irregularities, secondary amenorrhea, and increases in luteinizing hormone and follicle-stimulating hormone have occurred. Azoospermia and oligospermia have been observed in males. Females of reproductive potential should consider family planning options prior to therapy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307878\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (baseline and periodic), liver function, serum creatinine, urinary protein, and BUN (baseline and periodic); fasting serum glucose and lipid profile (baseline and periodic); monitor for signs and symptoms of infection, noninfectious pneumonitis, or malignancy</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">SEGA: Monitor everolimus whole blood trough concentrations approximately 2 weeks after treatment initiation, 2 weeks after dose modifications, and after initiation or dose modification of concomitant CYP3A4 and/or P-gp inducers or inhibitors.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Transplantation; liver or renal: Monitor whole blood trough concentrations (based on an LCMSMS assay method), especially in patients with hepatic impairment, with concomitant CYP3A4/P-gp inhibitors and inducers, and when cyclosporine formulations or doses are changed; dosage adjustments should be made on trough concentrations obtained 4 to 5 days after previous dosage adjustment; monitor cyclosporine concentrations and proteinuria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13307879\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Recommended range for everolimus whole blood trough concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SEGA: 5 to 15 ng/mL (high concentrations may be associated with larger reductions in SEGA volumes; responses have been observed at concentrations as low as 5 ng/mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transplantation; liver or renal: 3 to 8 ng/mL (based on LCMSMS assay method); in pediatric studies, reported target range: 3 to 6 ng/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7674209\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Everolimus is a macrolide immunosuppressant and a mechanistic target of rapamycin (mTOR) inhibitor which has antiproliferative and antiangiogenic properties, and also reduces lipoma volume in patients with angiomyolipoma. Reduces protein synthesis and cell proliferation by binding to the FK binding protein-12 (FKBP-12), an intracellular protein, to form a complex that inhibits activation of mTOR (mechanistic target of rapamycin) serine-threonine kinase activity. Also reduces angiogenesis by inhibiting vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF-1) expression. Angiomyolipomas may occur due to unregulated mTOR activity in TSC-associated renal angiomyolipoma (Budde 2012); everolimus reduces lipoma volume (Bissler 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7674192\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid (Kirchner 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Apparent V<sub>d</sub>: 128 to 589 L (Zortress); volume of distribution in pediatric renal transplant patients (3 to 16 years) lower than adults (Van Damme-Lombaerts 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~74% (Afinitor and Zortress)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively metabolized in the liver via CYP3A4; forms 6 weak metabolites (Afinitor and Zortress)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets: ~30% (Tabernero 2008 [Afinitor]); Systemic exposure reduced by 22% with a high-fat meal and by 32% with a light-fat meal (Afinitor); Systemic exposure reduced 16% with a high-fat meal (Zortress)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets for suspension (Afinitor): AUC equivalent to tablets although peak concentrations are 20% to 36% lower; steady state concentrations are similar; Systemic exposure reduced by 12% with a high-fat meal and by 30% with a low-fat meal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~30 hours (Afinitor and Zortress); in pediatric renal transplant patients (3 to 16 years), half-life similar to adult data (Van Damme-Lombaerts 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 1 to 2 hours (Afinitor and Zortress)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (80%, based on solid organ transplant studies); Urine (~5%, based on solid organ transplant studies); clearance in pediatric renal transplant patients lower than adults possibly due to distributive differences (Van Damme-Lombaerts 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49638935\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In patients with subependymal giant cell astrocytoma, the geometric mean C<sub>min</sub> values normalized to mg/m<sup>2</sup> dose in patients &lt;10 years and 10 to 18 years of age were lower by 54% and 40%, respectively, than those observed in adults, suggesting everolimus clearance was higher in pediatric patients (compared to adults).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12825622\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tablets for oral suspension (Afinitor Disperz):</b> Administer as a suspension only. Administer immediately after preparation; discard if not administered within 60 minutes after preparation. Prepare suspension in water only. Do not break or crush tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Preparation in an oral syringe:</i> Place dose into 10 mL oral syringe (maximum 10 mg/syringe; use an additional syringe for doses &gt;10 mg). Draw ~5 mL of water and ~4 mL of air into oral syringe; allow to sit (tip up) in a container until tablets are in suspension (3 minutes). Gently invert syringe 5 times immediately prior to administration; administer contents, then add ~5 mL water and ~4 mL of air to same syringe, swirl to suspend remaining particles and administer entire contents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Preparation in a small glass:</i> Place dose into a small glass (&le;100 mL) containing ~25 mL water (maximum 10 mg/glass; use an additional glass for doses &gt;10 mg); allow to sit until tablets are in suspension (3 minutes). Stir gently with spoon immediately prior to administration; administer contents, then add ~25 mL water to same glass, swirl with same spoon to suspend remaining particles and administer entire contents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Administer immediately after preparation; discard if not administered within 60 minutes after preparation.</p>\n    <div class=\"reference\">Afinitor and Afinitor Disperz (everolimus) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2017.</div>\r\n\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Tablets (Afinitor):</b> Although the manufacturer recommends that the tablets be swallowed whole, an oral liquid may be prepared using tablets (for patients unable to swallow tablets whole). Disperse tablet in ~30 mL (1 oz) of water; gently stir. Administer and rinse container with additional 30 mL (1 oz) water and administer to ensure entire dose is administered. Administer immediately after preparation.</p>\n    <div class=\"reference\">Afinitor (everolimus) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2012.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321944\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet,Dispersible</b> (Afinitor Disperz Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (1): $592.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (1): $598.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $623.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Afinitor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (1): $595.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $623.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (1): $623.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $623.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zortress Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (1): $10.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (1): $20.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75 mg (1): $30.46</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961948\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Advacan (IN);</li>\n      <li>Afinitor (AE, AR, AU, BB, BE, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EE, ES, FR, GB, HK, HR, ID, IE, IL, IS, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MY, NO, NZ, PH, PL, QA, RO, SA, SE, SG, SI, SK, TH, TR, TW, UA, VN, ZW);</li>\n      <li>Certican (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CN, CO, CU, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GR, HK, HN, HR, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LT, MT, MY, NL, NO, NZ, PE, PH, PK, PL, PT, PY, QA, RO, SA, SE, SG, SI, SK, TH, TR, TW, UY, VE, VN);</li>\n      <li>Sertykan (UA);</li>\n      <li>Vetubia (HR, RO);</li>\n      <li>Votubia (CH, CY, CZ, DE, DK, EE, ES, FR, GB, IE, LU, LV, MT, NO, PL, QA, SE);</li>\n      <li>Xevirol (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Afinitor and Afinitor Disperz (everolimus) [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Co; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bissler JJ, Kingswood JC, Zonnenberg BA, et al, &ldquo;Everolimus Therapy for Angiomyolipoma in Patients With Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis: Results From EXIST-2,&rdquo; <i>J Clin Oncology</i>, 2012, 30(Supp 5):356. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Budde K and Gaedeke J, &ldquo;Tuberous Sclerosis Complex-Associated Angiomyolipomas: Focus on mTOR Inhibition,&rdquo; <i>Am J Kidney Dis</i>, 2012, 59(2):276-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/everolimus-pediatric-drug-information/abstract-text/22130643/pubmed\" target=\"_blank\" id=\"22130643\">22130643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ettenger R, Hoyer PF, Grimm P, et al, &quot;Multicenter Trial of Everolimus in Pediatric Renal Transplant Recipients: Results at Three Year,&quot; <i>Pediatr Transplant</i>, 2008, (4):456-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/everolimus-pediatric-drug-information/abstract-text/18466433/pubmed\" target=\"_blank\" id=\"18466433\">18466433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoyer PF, Ettenger R, Kovarik JM, et al, &quot;Everolimus in Pediatric <i>de nova</i> Renal Transplant Patients,&quot; <i>Transplantation</i>, 2003, 75(12):2082-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/everolimus-pediatric-drug-information/abstract-text/12829916/pubmed\" target=\"_blank\" id=\"12829916\">12829916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirchner GI, Meier-Wiedenbach I, and Manns MP, &quot;Clinical Pharmacokinetics of Everolimus,&quot; <i>Clin Pharmacokinet</i>, 2004, 43(2):83-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/everolimus-pediatric-drug-information/abstract-text/14748618/pubmed\" target=\"_blank\" id=\"14748618\">14748618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kovarik JM, Sabia HD, Figueiredo J, et al, &quot;Influence of Hepatic Impairment on Everolimus Pharmacokinetics: Implications for Dose Adjustment,&quot; <i>Clin Pharmacol Ther</i>, 2001, 70(5):425-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/everolimus-pediatric-drug-information/abstract-text/11719728/pubmed\" target=\"_blank\" id=\"11719728\">11719728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krueger DA, Care MM, Holland K, et al, &quot;Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis,&quot; <i>N Engl J Med</i>, 2010, 363(19):1801-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/everolimus-pediatric-drug-information/abstract-text/21047224/pubmed\" target=\"_blank\" id=\"21047224\">21047224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lorber MI, Ponticelli C, Whelchel J, et al, &ldquo;Therapeutic Drug Monitoring for Everolimus in Kidney Transplantation Using 12-Month Exposure, Efficacy, and Safety Data,&rdquo; <i>Clin Transplant</i>, 2005, 19(2):145-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/everolimus-pediatric-drug-information/abstract-text/15740547/pubmed\" target=\"_blank\" id=\"15740547\">15740547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Donnell A, Faivre S, Burris HA 3rd, et al, &quot;Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors,&quot; <i>J Clin Oncol</i>, 2008, 26(10):1588-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/everolimus-pediatric-drug-information/abstract-text/18332470/pubmed\" target=\"_blank\" id=\"18332470\">18332470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pape L, Ahlenstiel T, Ehrich JH, et al, &quot;Reversal of Loss of Glomerular Filtration Rate in Children With Transplant Nephropathy After Switch to Everolimus and Low-Dose Cyclosporine A,&quot; <i>Pediatr Transplant</i>, 2007, 11(3):291-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/everolimus-pediatric-drug-information/abstract-text/17430485/pubmed\" target=\"_blank\" id=\"17430485\">17430485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pape L, Lehner F, Blume C, et al, &quot;Pediatric Kidney Transplantation Followed by <i>de novo</i> Therapy With Everolimus, Low-Dose Cyclosporine A, and Steroid Elimination: 3-Year Data,&quot; <i>Transplantation</i>, 2011, 92(6):658-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/everolimus-pediatric-drug-information/abstract-text/21804444/pubmed\" target=\"_blank\" id=\"21804444\">21804444</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pape L, Offner G, Kreuzer M, et al, &quot;<i>De novo</i> Therapy With Everolimus, Low-Dose Ciclosporine A, Basiliximab and Steroid Elimination in Pediatric Kidney Transplantation,&quot; <i>Am J Transplant</i>, 2010, 10(10):2349-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/everolimus-pediatric-drug-information/abstract-text/20840473/pubmed\" target=\"_blank\" id=\"20840473\">20840473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tabernero J, Rojo F, Calvo E, et al, &quot;Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors,&quot; J Clin Oncol. 2008 Apr 1;26(10):1603-10.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Damme-Lombaerts R, Webb NA, Hoyer PF, et al, &quot;Single-Dose Pharmacokinetics and Tolerability of Everolimus in Stable Pediatric Renal Transplant Patients,&quot; <i>Pediatr Transplant</i>, 2002, 6(2):147-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/everolimus-pediatric-drug-information/abstract-text/12000472/pubmed\" target=\"_blank\" id=\"12000472\">12000472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vester U, Kranz B, Wehr S, et al, &quot;Everolimus (Certican) in Combination With Neoral in Pediatric Renal Transplant Recipients: Interim Analysis After 3 Months,&quot; <i>Transplant Proc</i>, 2002, 34(6):2209-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/everolimus-pediatric-drug-information/abstract-text/12270366/pubmed\" target=\"_blank\" id=\"12270366\">12270366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zortress (everolimus) [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Co; January 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 17063 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F10223925\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7418605\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13209898\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F13307736\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F13307778\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F7674251\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F7674088\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F10223926\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13307877\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132489\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F7674865\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13307737\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7674085\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7674167\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7674098\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7674099\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9837969\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F7710406\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F7674191\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7674094\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13307878\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F13307879\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7674209\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F7674192\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F49638935\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F12825622\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321944\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961948\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/17063|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">Everolimus: Drug information</a></li><li><a href=\"topic.htm?path=everolimus-patient-drug-information\" class=\"drug drug_patient\">Everolimus: Patient drug information</a></li></ul></div></div>","javascript":null}